Kieran Ayling , Hannah Jackson , Ru Jia , Simon Royal , Lucy Fairclough , Kavita Vedhara
{"title":"Psychological correlates of antibody response to mRNA SARS-CoV-2 vaccination: A prospective observational cohort study","authors":"Kieran Ayling , Hannah Jackson , Ru Jia , Simon Royal , Lucy Fairclough , Kavita Vedhara","doi":"10.1016/j.bbi.2025.03.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Vaccines fundamentally changed the course of the COVID-19 pandemic, saving > 14 million lives within a year. However, vaccine-conferred protection showed inter-individual variability, with many identified correlates of protection (e.g., age) not amenable to change. This prospective observational cohort study examined whether modifiable psychological factors (depressive symptoms, anxiety, perceived stress and positive mood), which predict antibody responses to other vaccines, also influenced the effectiveness of COVID-19 vaccines. We focussed on novel mRNA vaccines as these conferred greater clinical protection and psychological correlates have not been investigated in these vaccines previously.</div></div><div><h3>Methods</h3><div>One-hundred and eighty-four adults attending a mass-vaccination centre in the UK received a two-dose BNT162b2 mRNA SARS-CoV-2 vaccine course, completed validated psychological measures, and provided blood samples prior to vaccination and 4 weeks following the second vaccine dose.</div></div><div><h3>Results</h3><div>In separate linear regression models controlling for pre-vaccination antibody levels, demographic and clinical factors, higher levels of depressive symptoms (β = -0.15 [95 % CI: −0.30, −0.01], <em>p</em> = 0.041, partial <em>f</em><sup>2</sup> = 0.009) and lower levels of positive mood (β = 0.16 [95 % CI: 0.01, 0.30], <em>p</em> = 0.036, partial <em>f</em><sup>2</sup> = 0.011) were significantly associated with lower SARS-CoV-2 spike-specific antibody levels following vaccination. No significant relationships were observed between measures of anxiety or perceived stress and antibody responses.</div></div><div><h3>Conclusions</h3><div>Lower levels of depressive symptoms and greater positive mood were associated with larger antibody responses following mRNA SARS-CoV-2 vaccination in a community sample attending for their first course of COVID-19 vaccinations. As both are amenable to change, they could offer mechanisms for enhancing vaccine effectiveness particularly among populations at greater risk of vaccine failure.</div></div>","PeriodicalId":9199,"journal":{"name":"Brain, Behavior, and Immunity","volume":"127 ","pages":"Pages 103-109"},"PeriodicalIF":8.8000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain, Behavior, and Immunity","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0889159125000972","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Vaccines fundamentally changed the course of the COVID-19 pandemic, saving > 14 million lives within a year. However, vaccine-conferred protection showed inter-individual variability, with many identified correlates of protection (e.g., age) not amenable to change. This prospective observational cohort study examined whether modifiable psychological factors (depressive symptoms, anxiety, perceived stress and positive mood), which predict antibody responses to other vaccines, also influenced the effectiveness of COVID-19 vaccines. We focussed on novel mRNA vaccines as these conferred greater clinical protection and psychological correlates have not been investigated in these vaccines previously.
Methods
One-hundred and eighty-four adults attending a mass-vaccination centre in the UK received a two-dose BNT162b2 mRNA SARS-CoV-2 vaccine course, completed validated psychological measures, and provided blood samples prior to vaccination and 4 weeks following the second vaccine dose.
Results
In separate linear regression models controlling for pre-vaccination antibody levels, demographic and clinical factors, higher levels of depressive symptoms (β = -0.15 [95 % CI: −0.30, −0.01], p = 0.041, partial f2 = 0.009) and lower levels of positive mood (β = 0.16 [95 % CI: 0.01, 0.30], p = 0.036, partial f2 = 0.011) were significantly associated with lower SARS-CoV-2 spike-specific antibody levels following vaccination. No significant relationships were observed between measures of anxiety or perceived stress and antibody responses.
Conclusions
Lower levels of depressive symptoms and greater positive mood were associated with larger antibody responses following mRNA SARS-CoV-2 vaccination in a community sample attending for their first course of COVID-19 vaccinations. As both are amenable to change, they could offer mechanisms for enhancing vaccine effectiveness particularly among populations at greater risk of vaccine failure.
期刊介绍:
Established in 1987, Brain, Behavior, and Immunity proudly serves as the official journal of the Psychoneuroimmunology Research Society (PNIRS). This pioneering journal is dedicated to publishing peer-reviewed basic, experimental, and clinical studies that explore the intricate interactions among behavioral, neural, endocrine, and immune systems in both humans and animals.
As an international and interdisciplinary platform, Brain, Behavior, and Immunity focuses on original research spanning neuroscience, immunology, integrative physiology, behavioral biology, psychiatry, psychology, and clinical medicine. The journal is inclusive of research conducted at various levels, including molecular, cellular, social, and whole organism perspectives. With a commitment to efficiency, the journal facilitates online submission and review, ensuring timely publication of experimental results. Manuscripts typically undergo peer review and are returned to authors within 30 days of submission. It's worth noting that Brain, Behavior, and Immunity, published eight times a year, does not impose submission fees or page charges, fostering an open and accessible platform for scientific discourse.